Janus Kinase Inhibitor Use in Adults Aged 65 Years and Older: A Clinical Review Across Atopic Dermatitis, Alopecia Areata, and Psoriasis
Journal of the American Academy of Dermatology · 2026-09
DOI: 10.1016/j.jaad.2026.09.075 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of the American Academy of Dermatology, 2026-09. Verfasst von Raymond Z Ezzat und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Lahey Hospital & Medical Center, Burlington, Massachusetts, USA.
Abstract (Originalsprache)
BACKGROUND: JAK inhibitors are increasingly used as systemic therapies for inflammatory dermatoses, but adults aged 65 and older are underrepresented in their clinical trials. OBJECTIVE: To synthesize the efficacy, safety, and regulatory evidence on JAK inhibitors in adults aged 65 and older with atopic dermatitis, alopecia areata, and psoriasis. METHODS: Clinical review synthesizing phase 3 trials, integrated safety analyses, real-world cohorts, and FDA/EMA labeling with age-stratified outcomes into practice recommendations (Supplementary Appendix 1B). RESULTS: In atopic dermatitis, upadacitinib 15 mg and abrocitinib 100 mg are effective in older adults, with higher doses generally avoided. In alopecia areata, baricitinib shows efficacy in small older-adult cohorts, while ritlecitinib data in this age group remain too limited for age-specific conclusions. In psoriasis, deucravacitinib provides durable responses and avoids boxed warnings for MACE or VTE, while catalytic JAK inhibitors for psoriatic arthritis need label-directed dosing and close monitoring. CONCLUSION: JAK inhibitors may be a reasonable option for carefully selected older adults, but the decision should be a deliberate one. It rests on disease-specific efficacy, baseline cardiovascular and oncologic risk, modifiable comorbidities, label-directed dosing, and close monitoring. Age-stratified data remain sparse, and each decision should be individualized.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Lahey Hospital & Medical Center, Burlington, Massachusetts, USA.
- Department of Dermatology, Lahey Hospital & Medical Center, Burlington, Massachusetts, USA; Department of Dermatology, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: maryanne.m.senna@lahey.org.
Zitieren
APA
Ezzat, R. Z., Paz, M., Kreytak, C., & Senna, M. M. (2026). Janus Kinase Inhibitor Use in Adults Aged 65 Years and Older: A Clinical Review Across Atopic Dermatitis, Alopecia Areata, and Psoriasis. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2026.09.075
Vancouver
Ezzat RZ, Paz M, Kreytak C, Senna MM. Janus Kinase Inhibitor Use in Adults Aged 65 Years and Older: A Clinical Review Across Atopic Dermatitis, Alopecia Areata, and Psoriasis. Journal of the American Academy of Dermatology. 2026. doi:10.1016/j.jaad.2026.09.075
BibTeX
@article{Ezzat2026,
author = {Ezzat, Raymond Z and Paz, Meshi and Kreytak, Caroline and Senna, Maryanne M},
title = {Janus Kinase Inhibitor Use in Adults Aged 65 Years and Older: A Clinical Review Across Atopic Dermatitis, Alopecia Areata, and Psoriasis},
journal = {Journal of the American Academy of Dermatology},
year = {2026},
doi = {10.1016/j.jaad.2026.09.075}
}
EUVIMED